Third-generation CAR T Cells within the Heidelberg CAR Trial 1 (HD-CAR-1) Display an Excellent Safety Profile and Might Improve Persistence of CAR T Cells

被引：0
|
作者：
Schubert, Maria-Luisa [1 ]
Schmitt, Anita [1 ]
Hueckelhoven-Krauss, Angela [1 ]
Neuber, Brigitte [1 ]
Kunz, Alexander [1 ]
Wang, Lei [1 ]
Michels, Birgit [1 ]
Gern, Ulrike [1 ]
Sellner, Leopold [1 ]
Hofmann, Susanne [1 ]
Pavel, Petra [2 ]
Ho, Anthony [1 ]
Mueller-Tidow, Carsten [1 ]
Dreger, Peter [1 ]
Schmitt, Michael [1 ]
机构：
[1] Univ Heidelberg Hosp, Heidelberg, Germany
[2] German Red Cross Blood Serv Baden Wuerttemberg He, Heidelberg, Germany
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O036
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [1] Third-generation chimeric antigen receptor (CAR) T cells in patients with lymphoid disease - results of the Heidelberg trial 1 (HD-CAR-1 trial)
    Schubert, M. L.
    Schmitt, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Kunz, A.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Sellner, L.
    Korell, F.
    Hofmann, S.
    Pavel, P.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 122 - 123
  • [2] Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients
    Schubert, Maria-Luisa
    Schmitt, Anita
    Neuber, Brigitte
    Huckelhoven-Krauss, Angela
    Kunz, Alexander
    Wang, Lei
    Gern, Ulrike
    Michels, Birgit
    Sellner, Leopold
    Hofmann, Susanne
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    [J]. BLOOD, 2019, 134
  • [3] Treatment with CD19-directed third-generation chimeric antigen receptor (CAR) T cells - results of the Heidelberg trial 1 (HD-CAR-1 Trial)
    Schubert, M. -L.
    Schmitt, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Kunz, A.
    Wang, L.
    Gern, U.
    Michels, B.
    Hofmann, S.
    Pavel, P.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 33 - 34
  • [4] Treatment of adult all patients with third-generation CD19-directed chimeric antigen receptor (CAR) T cells - results of the Heidelberg Trial 1 (HD-CAR-1 trial)
    Schubert, M. L.
    Schmitt, A.
    Kunz, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Derigs, P.
    Haas, D.
    Pavel, P.
    Vonficht, D.
    Haas, S.
    Bug, G.
    Casper, J.
    Goerner, M.
    Finke, J.
    Neubauer, A.
    Ringhoffer, M.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    [J]. BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 27 - 28
  • [5] Third-generation CAR T cell therapy targeting relapsed or refractory CD19+lymphoid disease (HD-CAR-1)
    Schubert, M. -L.
    Schmitt, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Kunz, A.
    Wang, L.
    Gern, U.
    Michels, B.
    Sellner, L.
    Hofmann, S.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 236 - 236
  • [6] Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)
    Schubert, Maria-Luisa
    Schmitt, Anita
    Neuber, Brigitte
    Hueckelhoven-Krauss, Angela
    Kunz, Alexander
    Wang, Lei
    Michels, Birgit
    Waldhoff, Philip
    Sellner, Leopold
    Korell, Felix
    Hofmann, Susanne
    Pavel, Petra
    Ho, Anthony D.
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    [J]. BLOOD, 2021, 138
  • [7] The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
    Bachmann, Michael
    [J]. IMMUNOLOGY LETTERS, 2019, 211 : 13 - 22
  • [8] Treatment of Patients with CD19-directed Chimeric Antigen Receptor (CAR) T Cells of third Generation - updated Results from the Heidelberg Study 1 (HD-CAR-1 Study) with a Focus on the ALL Patient Cohort
    Schubert, M. -L.
    Schmitt, A.
    Kunz, A.
    Neuber, B.
    Huckelhoven-Krauss, A.
    Waldhoff, P.
    Wang, L.
    Michels, B.
    Korell, F.
    Derigs, P.
    Haas, D.
    Pavel, P.
    Vonficht, D.
    Haas, S.
    Ayuk, F. A.
    Bug, G.
    Lang, F.
    Gokbuget, N.
    Casper, J.
    Gorner, M.
    Finke, J.
    Neubauer, A.
    Ringhoffer, M.
    Bruggemann, M.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 43 - 43
  • [9] Third Generation CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed or Refractory Chronic Lymphocytic Leukemia - Update of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Bruggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Laier, S.
    Ho, A. D.
    Muller-Tidow, C.
    Schmitt, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 41 - 42
  • [10] Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
    Fredon, Maxime
    Poussard, Margaux
    Biichle, Sabeha
    Bonnefoy, Francis
    Mantion, Charles-Frederic
    Seffar, Evan
    Renosi, Florian
    Bole-Richard, Elodie
    Boidot, Romain
    Chevrier, Sandrine
    Anna, Francois
    Loustau, Maria
    Caumartin, Julien
    Goncalves-Venturelli, Mathieu
    Robinet, Eric
    Saas, Philippe
    Deconinck, Eric
    Daguidau, Etienne
    Roussel, Xavier
    Godet, Yann
    Adotevi, Olivier
    Angelot-Delettre, Fanny
    Galaine, Jeanne
    Garnache-Ottou, Francine
    [J]. CANCER IMMUNOLOGY RESEARCH, 2024, 12 (08) : 1090 - 1107
12345